Leading Skin Cancer Research from the Dermatology Clinic

Rubeta Matin is a Consultant Dermatologist with an interest in Cutaneous Oncology based at Oxford University Hospitals NHS Foundation Trust. Her research career stems from a MRC Clinical Training Fellowship investigating treatment resistance of melanoma (2006-2009), which led to a PhD in Molecular Mechanisms in Melanoma. She is Dermatology Research Lead for Skin Cancer and runs an active clinical research programme, currently Chief Investigator for four clinical trials and Principal Investigator for five trials.

 “As a clinician I work at the interface with patients ensuring that the research that I do is always focused on improving patient outcomes.” 

Early skin cancer diagnosis and prevention

Rubeta is a core member of the Cochrane Skin Cancer Diagnostic Test Accuracy Group co-authoring a suite of systematic reviews evaluating diagnosis and staging of skin cancers. She also leads an international commercial collaboration testing a novel digital dermatoscope in secondary care aimed to enhance diagnostic accuracy.

Skin toxicity associated with targeted treatments  / immunotherapy in metastatic melanoma. 

Rubeta is collaborating with the Medical Oncology Melanoma Team to investigate the clinicopathological diversity of skin toxicities and T-cell responses in the skin of melanoma patients treated with immune-checkpoint blockers. Skin reactions are the most frequent and earliest side effects of immune checkpoint inhibitors which are used to treat metastatic melanoma and increasingly used in other cancers. The clinical and molecular features of skin toxicity are poorly characterised and many individuals are not managed by dermatologists with expertise in these novel toxicities.

Patient Reported Outcomes 

As leader of a workstream evaluating Patient Reported Outcome (PRO) in skin cancers in collaboration with NIHR Collaboration for Leadership in Applied Health Research & Care (CLAHRC), Rubeta’s research seeks to improve care by integrating patient perspectives. She has collaborated with the CLAHRC patient experiences and patient reported outcomes theme evaluating feasibility of using the Skin Cancer Quality of Life Impact Tool in skin cancer screening clinics.

Collaborators in Oxford include Mark Middleton, Benjamin Fairfax and Miranda Payne (Medical Oncology), Crispin Jenkinson and Ray Fitzpatrick (Patient Reported Outcomes), and Graham Collins (Haematology). National collaborators are Catherine Harwood (Barts Health Trust) and Charlotte Proby (Dundee).

Rubeta is funded by NIHR Research for Patient Benefit Grant, Skin Cancer Research Fund, UK Dermatology Clinical Trials Network Themed Call Research Fund, and Oxfordshire Health Services Research Committee.

Find out more about our research below

Tackling blood cancers in Tanzania and Uganda

Scientists from Tanzania, Uganda and Oxford University have teamed up in a new child blood cancer program

Epigenetic markers for melanoma patient response to ICB therapy

Development fund winners Rosalin Cooper & Ben Fairfax are investigating the epigenetic landscape of melanoma patients and how it can impact patient sensitivity to ICB therapy

New melanoma cancer drug in development shows promise

University of Oxford and Immunocore Ltd have investigated Tebentafusp, a new anti-tumor immune response drug for patients with metastatic melanoma

The relationship between unexpected weight loss & cancer

New research will help GPs to identify the signs they should look for to swiftly diagnose cancer in people with unexpected weight loss

Researchers discover mutation that determines treatment efficiency

Weatherall Institute of Molecular Medicine researchers have recently discovered why a class of cancer drugs is beneficial only in a subset of patients

Mapping the T-cell landscape of pancreatic cancer

Through analysis of T-cell populations, researchers Drs Enas Abu-Shah & Shivan Sivakumar identify novel therapeutic opportunities in pancreatic cancer patients

Oxford to lead new programme of AI research to improve lung cancer screening

Science Minister Amanda Solloway today announced Oxford will lead a new national programme of AI research to improve lung cancer screening

New start-up Base Genomics launches

Base Genomics is based on Dr Chunxiao Song’s innovative TAPS technology, break-through Oxford-developed DNA methylation technology

Tackling oesophageal cancer early detection challenges through AI

Dr Sharib Ali specialises in the applications of AI to early oesophageal cancer detection